Kaiser Foundation Hospitals

Kaiser Foundation Hospitals, operating through its Kaiser Foundation Research Institute division and doing business as Kaiser Permanente, is a non-profit integrated healthcare system and research organization that receives federal research contracts and grants as a prime recipient and subcontractor, with no SBA set-aside designations across its federal footprint. Based in Oakland, California, Kaiser Permanente operates as a parent entity within the Kaiser Foundation Health Plan corporate structure and competes predominantly full-and-open, leveraging its integrated healthcare delivery system, comprehensive electronic health records across 4.5 million diverse members, and established research infrastructure to support federal public health and biomedical research priorities across clinical epidemiology, vaccine safety surveillance, evidence-based practice development, and health disparities research.

Kaiser Permanente's federal work clusters heavily in infectious disease, cardiovascular health, cancer research, and implementation science delivered to the National Institutes of Health (particularly the National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute on Aging), the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the Food and Drug Administration. Over the past several years, the vendor has grown its prime award volume from 70 awards in 2022 to 207 in 2024, with 208 awards in 2025, demonstrating sustained federal research demand. Recent representative contract work includes a $20.1 million delivery order from the National Cancer Institute for CONNECT Task Order 8 cohort recruitment and management under the Cancer Study Cohort Recruitment IDV; a $11.5 million CDC contract for epidemiological studies and clinical immunization safety assessment; systematic evidence review delivery orders from AHRQ totaling $3.6 million and $450,000 supporting U.S. Preventive Services Task Force priorities; and a $1.09 million delivery order from the National Heart, Lung, and Blood Institute for continued support of the Coronary Artery Risk Development in Young Adults (CARDIA) Study Oakland Field Center. Grant work includes a $5.04 million National Institute on Minority Health and Health Disparities award examining racial and ethnic disparities in depression treatment across five health systems in seven states, a $3.92 million National Heart, Lung, and Blood Institute grant for the HIDDEN-ASCVD study developing artificial intelligence algorithms for coronary artery calcium detection, and a $2.496 million National Institute on Aging grant investigating missed home health care in older adults with Alzheimer's disease and related dementias.

Customer concentration is heavily skewed to HHS agencies. The top five federal customers account for approximately 50 percent of recent award count: the National Cancer Institute (242 awards, $204 million combined potential value), a subsidiary NIH entity (139 awards, $100 thousand), CDC Pittsburgh (122 awards, $2 billion combined potential value), the National Heart, Lung, and Blood Institute (110 awards, $191.3 million), and the National Institute on Aging (108 awards, $25 thousand). By potential value, CDC Pittsburgh dominates at $2 billion (more than 50 percent of combined dollars), followed by the Food and Drug Administration ($221.5 million), the National Cancer Institute ($204 million), and the National Heart, Lung, and Blood Institute ($191.3 million). This split reflects Kaiser Permanente's heavy engagement in vaccine safety surveillance and infectious disease epidemiology anchored by CDC relationships, counterbalanced by substantial cancer research and aging-focused grant awards from NIH institutes.

Kaiser Permanente maintains multiple parent contract vehicles supporting ongoing task order issuance. The Vaccine Safety Datalink Project IDV carries the largest task order load—60 task orders valued at $137.6 million combined potential value—reflecting Kaiser Permanente's role as a key integrated healthcare system partner in CDC vaccine safety surveillance. The Evidence-based Practice Centers VI IDIQ supports 11 task orders worth $19.2 million, with Kaiser Permanente holding a $90 million multiple-award indefinite delivery contract effective July 1, 2025 through June 30, 2030 under the Evidence-based Practice Centers VII program, positioning the vendor to continue evidence synthesis work for AHRQ. The Clinical Immunization Safety Assessment (CISA) Base IDIQ, an $86 million multiple-award vehicle through September 2028, has generated 10 task orders valued at $2.8 million. The Coronary Artery Risk Development in Young Adults (CARDIA) Study IDV, an $11 million multiple-award contract through June 30, 2034, supports Kaiser Permanente's role as the Oakland field center. These vehicles establish Kaiser Permanente as an established research partner capable of sustained longitudinal data collection and epidemiological analysis across federal health agencies.

Within the next twenty-four months, 99 awards reach ultimate completion, carrying combined potential value of $118.2 million and representing a significant recompete opportunity. Growth trajectory shows steady year-over-year increases through 2025, with 208 awards obligated in 2025 (up from 207 in 2024), though 2026 year-to-date counts (52 awards as of mid-July) suggest mid-year reporting or award timing variation rather than decline.

Kaiser Permanente operates predominantly as a prime contractor—904 of 1,430 total awards (63 percent) carry prime designation. The vendor maintains substantial subcontractor relationships across its research footprint, delivering work as a sub-recipient on NIH and academic-led research initiatives while retaining primary research infrastructure and data management responsibilities. Across SCI-reportable prime service contracts, subcontractors account for 9 percent of total contractor hours, with 60 named subcontractors reported. SCI-reported invoicing of $133.4 million across FY2022–FY2024 reflects federal services activity alone: FY2022 invoicing reached $32.2 million (95.5 FTEs), FY2023 invoicing $52.4 million (112 FTEs), and FY2024 invoicing $48.8 million (113 FTEs). On federal services contracts captured in SCI, median government-paid rates ran around $161/hr, with senior labor pricing reaching $423/hr and entry-level labor around $87/hr.

Kaiser Permanente frequently subcontracts to leading academic medical centers and research universities as a data and cohort sourcing partner. Named sub-award relationships as a subrecipient include Columbia University, Johns Hopkins University, University of Pennsylvania, University of Washington, Duke University, Yale School of Medicine, and UCLA, where Kaiser Permanente typically contributes electronic health record data extraction, cohort identification, IRB management, and analysis support. As a prime contractor, Kaiser Permanente engages subcontractors including Ochin, Inc. (for community health center implementation research), University of Arizona, University of New Mexico Health Sciences Center, and University of Washington (as collaborative partners in the EXHALE lung cancer screening implementation study), and regional health systems and academic partners for site-specific activities in multi-site federally funded research networks.

Kaiser Permanente's grant portfolio reflects recipient status across NIH institutes and FDA, with recent awards totaling more than $30 million in aggregate across FY2026 alone. The vendor has received cooperative agreements from the National Cancer Institute under the 21st Century Cures Act Beau Biden Cancer Moonshot program ($1.684 million for the EXHALE lung cancer screening project) and the National Institute of Neurological Disorders and Stroke ($1.89 million for the CARNATION pain management technology implementation study), positioning Kaiser Permanente as an implementer and evaluator of health services innovations in real-world care settings. Sub-awardee relationships on Kaiser-led grants include University of California at Los Angeles, Stanford University, Yale School of Medicine, and the Information and Referral Federation of Los Angeles County. These grant relationships frequently leverage Kaiser Permanente's integrated health system data and patient engagement infrastructure to conduct pragmatic trials and implementation research that translates evidence into scalable clinical and public health practice improvements.

Kaiser Permanente's federal research practice centers on health services research, epidemiological analysis, and clinical outcomes evaluation grounded in comprehensive longitudinal patient data. The organization does not manufacture products or deliver traditional IT services; instead, it monetizes its role as a health system with extensive electronic health records, diverse patient populations representative of U.S. demographics, established research operations, and multidisciplinary investigative expertise in cardiovascular disease, oncology, infectious disease, maternal and child health, mental health, substance use disorders, and health disparities. This capability profile positions Kaiser Permanente as a strategic partner for federal agencies designing population-based studies, vaccine safety surveillance, and implementation science initiatives that require integration of clinical data, patient recruitment, and real-world health outcomes evidence generation.